2 completed, 1 not yet recruiting, 1 no longer available, 1 withdrawn. 1 Phase 1, 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow CMV Disease: new trials by email Literature Review of CMV Disease trials Research Report on CMV Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Letermovir vs Valganciclovir in CMV R+ Kidney Transplant Letermovir, Valganciclovir CMV Prophylaxis - CMV Infection, CMV | Phase 4 | Not yet recruiting | Elisabeth Kincaide | 300 | 2026-05-01 | 2026-05-08 |
| Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002) Letermovir, Valganciclovir, Acyclovir (ACV) - CMV Disease | Phase 3 | Completed | Merck Sharp & Dohme LLC | 601 | 2018-05-03 | 2023-07-28 |
| Adoptive Immunotherapy for CMV Disease CMV vaccine - CMV Disease | Phase 1 / Phase 2 | Withdrawn | Hadassah Medical Organization | 20 | 2004-02-01 | 2011-04-08 |
| Long Term Use of Valganciclovir for Prophylaxis of CMV Disease in Kidney and Pancreas Transplant Patients CMV Disease, Viral Resistance | Completed | University of Massachusetts, Worcester | 100 | 2003-10-01 | 2005-09-23 | |
| Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs) - CMV Viremia, CMV Disease | No longer available | Atara Biotherapeutics | 2019-04-08 |
Cytomegalovirus Infections (2) · Acquired Immunodeficiency Syndrome (1) · Death (1) · Neutropenia (1) · Rejection, Psychology (1)
DNA Virus Infections (2) · Herpesviridae Infections (2) · Infections (2) · Virus Diseases (2) · Agranulocytosis (1) · Behavior (1) · Blood-Borne Infections (1) · Communicable Diseases (1) · Cytopenia (1) · Genital Diseases (1) · HIV Infections (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1)
letermovir (2) · Acyclovir (1) · Valganciclovir (1) · mRNA-1647 cytomegalovirus vaccine (1)
Atara Biotherapeutics (1) · Elisabeth Kincaide (1) · Hadassah Medical Organization (1) · Merck Sharp & Dohme LLC (1) · University of Massachusetts, Worcester (1)
United States (3) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Colombia (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Mexico (1) · New Zealand (1) · Poland (1)
Marc E Uknis, MD (1) · Shimon Slavin, MD (1) · Willis Navarro, MD (1)
PMID 37279999, PMID 38700045, PMID 38853607, PMID 41321121, PMID 42639594
2017 (1)